NCT05174156View on ClinicalTrials.gov

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Advanced Esophageal Cancer
Interventions
DRUG

Combination therapy

SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin

Trial Locations (1)

510655

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Nanjing Geneseeq Technology Inc.

INDUSTRY

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER